Physician profile
John J Bergin
NPI 1073040382
$2,477.83
in general payments reported to CMS, 2019-2025
43 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2022: $206 · 2023: $156 · 2024: $100 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $349.74 | 2022-2024 | Truebeam, Eclipse Treatment Planning System For External Beam Radiation Therapy, Aria Radiation Therapy Management Software |
| Astrazeneca Pharmaceuticals LP | $208.44 | 2019-2025 | Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $202.64 | 2025 | Keytruda, Welireg, Lynparza |
| Boston Scientific Corporation | $172.72 | 2019-2023 | Spaceoar Vue System - 10ml |
| Regeneron Healthcare Solutions, INC. | $107.64 | 2025 | Libtayo |
| Janssen Biotech, INC. | $106.91 | 2024-2025 | Erleada, Darzalex, Rybrevant |
| Glaxosmithkline, LLC. | $99.99 | 2025 | Ojjaara, Blenrep |
| Novartis Pharmaceuticals Corporation | $92.67 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.89 | 2025 | |
| Stemline Therapeutics INC. | $69.43 | 2025 | Orserdu |
| Sobi, INC | $63.00 | 2025 | |
| Servier Pharmaceuticals LLC | $60.00 | 2025 | |
| Elekta, INC. | $58.54 | 2024 | Elekta Medical Linear Accelerator |
| Teleflex LLC | $57.58 | 2025 | Barrigel |
| Takeda Pharmaceuticals U.S.A., INC. | $51.80 | 2025 | Fruzaqla, Ninlaro |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $46.98 | 2025 | Polivy, Venclexta |
| Lilly USA, LLC | $46.68 | 2025 | Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $42.69 | 2025 | Opdivo |
| Immunocore Limited | $42.38 | 2025 | Kimmtrak |
| Dendreon Pharmaceuticals LLC | $34.37 | 2025 | Provenge |
| Blue Earth Diagnostics | $27.73 | 2025 | Posluma |
| Agios Pharmaceuticals, INC. | $27.51 | 2025 | Pyrukynd |
| Gilead Sciences, INC. | $27.35 | 2025 | Trodelvy |
| Caris Mpi, INC. | $27.28 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $26.23 | 2025 | Jakafi |
| Geron Corporation | $26.22 | 2025 | Rytelo |
| Legend Biotech USA INC. | $24.86 | 2025 | Carvykti |
| Daiichi Sankyo INC. | $21.72 | 2025 | Enhertu |
| Emd Serono, INC. | $21.57 | 2025 | |
| Myriad Genetic Laboratories, INC. | $21.14 | 2025 | Prolaris |
| Genzyme Corporation | $20.73 | 2025 | |
| Astellas Pharma US INC | $20.68 | 2025 | Padcev |
| Telix Pharmaceuticals | $20.28 | 2025 | Illuccix |
| Abbvie INC. | $19.85 | 2025 | |
| Exelixis INC. | $19.67 | 2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $17.92 | 2025 | Onivyde |
| Sumitomo Pharma America, INC. | $17.69 | 2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $17.25 | 2025 | |
| Spectrum Pharmaceuticals INC. | $16.87 | 2025 | Rolvedon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.63 | 2025 | |
| Novocure INC. | $15.60 | 2025 | Optune Lua (Novottf-200t) |
| Pfizer INC. | $15.33 | 2025 | |
| Eisai INC. | $14.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.